A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study Designed to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profile of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2018
At a glance
- Drugs Bertilimumab (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Immune Pharmaceuticals Inc
- 31 Aug 2018 Biomarkers information updated
- 20 Feb 2018 According to Immune Pharmaceuticals media release, company will copmlete enrollment in Q3 2018.and Report top-line results in Q1 2019.
- 05 Jan 2018 Planned End Date changed from 1 Apr 2017 to 1 Mar 2019.